Certificate of Analysis (COA) View the laboratory certificate for this product [ View COA ]

UPA UPRET 60 Retatrutide 60mg | Peptide Aesthetix

R 2,700.00
Add to WishlistCompare

UPA UPRET 60 is a high-strength 60mg retatrutide research peptide supplied in a multidose vial presentation. Retatrutide is an investigational triple-receptor agonist that has been studied for its activity at the GLP-1, GIP and glucagon (GCG) receptors. 

The supplied UPA presentation includes 1 × 60mg multidose vial and 1 × 2mL bacteriostatic water ampoule, according to the manufacturer's current product information and the packaging shown. 

Key Features
  • Brand: UPA / Peptide Aesthetix
  • Product: UPRET 60
  • Compound: Retatrutide
  • Strength: 60mg
  • Format: Multidose vial
  • Included: 2mL bacteriostatic water, as listed by UPA
  • Receptor activity: GLP-1 / GIP / GCG
  • Research category: Metabolic & peptide research
  • Research focus: Metabolic signalling, glucose regulation, body composition and energy balance 
Dosage & Usage

Retatrutide is an investigational multi-receptor peptide studied in GLP-1, GIP and glucagon receptor signalling, metabolic regulation, glucose physiology, energy expenditure and body-composition research. Experimental concentrations and study parameters should be determined according to relevant scientific literature and validated laboratory procedures. No human dosing or administration protocol is provided.

FAQ's & Tips

What is UPA UPRET 60?

UPRET 60 is a 60mg retatrutide research peptide product marketed by UPA / Peptide Aesthetix. 

What is retatrutide?

Retatrutide is an investigational peptide that acts on the GLP-1, GIP and glucagon receptors.

What does "triple agonist" mean?

It refers to activity at three receptor pathways: GLP-1, GIP and GCG.

How much retatrutide is in UPRET 60?

The product is labelled as containing 60mg retatrutide. 

What is included with the UPA product?

UPA lists 1 × 60mg multidose vial together with 1 × 2mL bacteriostatic water ampoule.

Research

Retatrutide is an investigational triple agonist targeting GLP-1, GIP and glucagon receptors. Research has evaluated the combined effects of these pathways on metabolic regulation and body composition.

The GLP-1 and GIP components are associated with incretin signalling, while glucagon receptor activity introduces an additional pathway involved in energy expenditure and substrate metabolism. The combination is an important area of investigation in obesity and metabolic-disease research. 

Current retatrutide research remains investigational, and the compound should not be presented as an established approved therapy based solely on its mechanism or early research findings.

Reviews